Physician profile
Arthur Yan
NPI 1437354164
$5,213.95
in general payments reported to CMS, 2019-2025
25 companies · $1,443 in 2025
The $1,443 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $45.65 · 2022: $370 · 2023: $1,878 · 2024: $1,477 · 2025: $1,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,722 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,722.03 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,144.80 | 2022-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $760.70 | 2022-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $432.20 | 2022-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $430.08 | 2022-2025 | Entyvio, Eohilia, Vpriv |
| Regeneron Healthcare Solutions, INC. | $367.94 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $339.36 | 2020-2025 | Ocaliva |
| Genzyme Corporation | $289.37 | 2023-2025 | |
| Pfizer INC. | $228.84 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $200.15 | 2023-2025 | Voquezna |
| Celgene Corporation | $165.77 | 2023 | Zeposia |
| Ardelyx, INC. | $143.79 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $110.83 | 2023 | Rebyota, Clenpiq |
| Braintree Laboratories, INC. | $103.65 | 2022-2025 | Sutab, Suflave |
| Vivus LLC | $76.57 | 2024-2025 | Qsymia, Pancreaze |
| Lilly USA, LLC | $61.24 | 2024-2025 | Omvoh |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $52.82 | 2022-2023 | Dificid, Zinplava |
| Gilead Sciences, INC. | $49.61 | 2023-2025 | |
| Qol Medical, LLC | $48.50 | 2023 | Sucraid |
| Medtronic, INC. | $37.30 | 2023 | Pillcam |
| Madrigal Pharmaceuticals | $36.36 | 2025 | Rezdiffra |
| Cook Medical LLC | $36.21 | 2025 | Hemospray |
| Orphalan INC | $31.70 | 2024 | Cuvrior |
| Capsovision, INC. | $28.37 | 2024 | Capsocam Plus |
| Celltrion USA INC. | $19.27 | 2024 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $18.52 | 2024 | Bylvay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Yan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.